Literature DB >> 23419204

Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.

Andrew Paul DeFilippis1, Michael J Blaha, Seth S Martin, Robert M Reed, Steven R Jones, Khurram Nasir, Roger S Blumenthal, Matthew J Budoff.   

Abstract

OBJECTIVE: While nonalcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome, it is not known if NAFLD plays an independent role in the atherogenic dyslipidemia phenotype. METHODS AND
RESULTS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a population-based prospective cohort study of adults free of clinical cardiovascular disease at enrollment. We tested for a relationship between NAFLD, defined as a liver/spleen (L/S) attenuation ratio of <1 on a non-contrast cardiac CT scan, and multiple measures of fasting serum lipoprotein size, cholesterol and particle concentrations. NAFLD was present in 569 (17%) of 3362 participants. After adjustment for multiple metabolic risk factors, adiposity and measures of insulin resistance (HOMA-IR), NAFLD was independently associated with higher fasting serum triglycerides and lower serum HDL-C. Despite a lack of association with LDL-C, NAFLD was associated with higher LDL particle concentration and lower LDL particle size. Modeling the L/S ratio as a continuous variable, a severity dependent association was observed between atherogenic lipoprotein abnormalities and NAFLD.
CONCLUSION: In a large, multi-ethnic, gender balanced cohort, CT-diagnosed NAFLD was associated with the atherogenic dyslipidemia phenotype in a dose dependent fashion. These relationships persisted after adjustment for several metabolic risk factors and HOMA-IR, suggesting a possible independent pathophysiologic role between NAFLD and dyslipidemia.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23419204      PMCID: PMC4049078          DOI: 10.1016/j.atherosclerosis.2013.01.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  57 in total

1.  Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano
Journal:  Radiology       Date:  2005-01       Impact factor: 11.105

2.  Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.

Authors:  Frederico G S Toledo; Allan D Sniderman; David E Kelley
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

3.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.

Authors:  A Zambon; J E Hokanson; B G Brown; J D Brunzell
Journal:  Circulation       Date:  1999-04-20       Impact factor: 29.690

6.  Quantitative evaluation of fatty liver by computed tomography in rabbits.

Authors:  R Kawata; K Sakata; T Kunieda; S Saji; H Doi; Y Nozawa
Journal:  AJR Am J Roentgenol       Date:  1984-04       Impact factor: 3.959

7.  Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity.

Authors:  Dick C Chan; Gerald F Watts; SengKhee Gan; Annette T Y Wong; Esther M M Ooi; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-11       Impact factor: 8.311

8.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

9.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

10.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Authors:  Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

View more
  68 in total

Review 1.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

2.  Lycopene and apo-10'-lycopenoic acid have differential mechanisms of protection against hepatic steatosis in β-carotene-9',10'-oxygenase knockout male mice.

Authors:  Blanche C Ip; Chun Liu; Alice H Lichtenstein; Johannes von Lintig; Xiang-Dong Wang
Journal:  J Nutr       Date:  2014-12-10       Impact factor: 4.798

3.  Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study.

Authors:  Lisa B VanWagner; Hongyan Ning; Cora E Lewis; Christina M Shay; John Wilkins; J Jeffrey Carr; James G Terry; Donald M Lloyd-Jones; David R Jacobs; Mercedes R Carnethon
Journal:  Atherosclerosis       Date:  2014-06-10       Impact factor: 5.162

Review 4.  Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.

Authors:  Eric M Przybyszewski; Giovanni Targher; Michael Roden; Kathleen E Corey
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

5.  Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.

Authors:  Lisa B VanWagner; Brittany Lapin; Anton I Skaro; Donald M Lloyd-Jones; Mary E Rinella
Journal:  Liver Int       Date:  2015-06-03       Impact factor: 5.828

6.  Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort.

Authors:  Xianghai Zhou; Yufeng Li; Xiuying Zhang; Ying Ying Guan; Yindra Puentes; Fang Zhang; Elizabeth K Speliotes; Linong Ji
Journal:  Diabetes Metab Res Rev       Date:  2019-04-17       Impact factor: 4.876

Review 7.  Nonalcoholic fatty liver disease and cardiovascular disease.

Authors:  Hong Liu; Hong-Yun Lu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 8.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

Review 9.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

10.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.

Authors:  Mohammad S Siddiqui; Michael Fuchs; Michael O Idowu; Velimir A Luketic; Sherry Boyett; Carol Sargeant; Richard T Stravitz; Puneet Puri; Scott Matherly; Richard K Sterling; Melissa Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-13       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.